Details
| Original language | English |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | Prostaglandins Leukotrienes and Essential Fatty Acids |
| Volume | 89 |
| Issue number | 1 |
| Publication status | Published - Jul 2013 |
Abstract
Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5n-3) and Docosahexaenoic acid (DHA 22:6n-3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.
Keywords
- Biological Availability, Dietary Supplements, Docosahexaenoic Acids/administration & dosage, Eicosapentaenoic Acid/administration & dosage, Fatty Acids, Omega-3/administration & dosage, Humans, Models, Biological
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 89, No. 1, 07.2013, p. 1-8.
Research output: Contribution to journal › Review article › Research › peer review
}
TY - JOUR
T1 - Bioavailability of long-chain omega-3 fatty acids
AU - Schuchardt, Jan Philipp
AU - Hahn, Andreas
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/7
Y1 - 2013/7
N2 - Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5n-3) and Docosahexaenoic acid (DHA 22:6n-3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.
AB - Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5n-3) and Docosahexaenoic acid (DHA 22:6n-3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.
KW - Biological Availability
KW - Dietary Supplements
KW - Docosahexaenoic Acids/administration & dosage
KW - Eicosapentaenoic Acid/administration & dosage
KW - Fatty Acids, Omega-3/administration & dosage
KW - Humans
KW - Models, Biological
U2 - 10.1016/j.plefa.2013.03.010
DO - 10.1016/j.plefa.2013.03.010
M3 - Review article
C2 - 23676322
VL - 89
SP - 1
EP - 8
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
SN - 0952-3278
IS - 1
ER -